M0220 HCPCS code: Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring

M0220 is the HCPCS Level II code for injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring. CMS terminated M0220 on 2024-12-12; do not bill it for later dates of service. In 2023 Medicare paid an average of $144.54 per service for M0220 across 1,069 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. Medicare volume fell 97% from 2022 to 2023 (36,087 to 1,069 services). In 2023, about 556 clinicians billed Medicare for M0220 for 1,069 beneficiaries; Florida, California, Pennsylvania accounted for 39% of services.

Code details

FieldValue
SectionM codes — Medical services and quality measures
Coverage codeC — Carrier judgment
Pricing indicator54
BETOS categoryO1G — Immunizations/vaccinations
Added2021-12-08
Last action effective2024-12-13
Terminated2024-12-12

Who bills M0220 (2023)

MeasureValue
Clinicians billing (by place of service)556
Medicare beneficiaries1,069
States with claims26
Share of services in top 3 states (Florida, California, Pennsylvania)39%

Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.

Medicare utilization for M0220, 2022–2023

YearServicesBeneficiariesAvg. allowedAvg. paid
202236,08725,816$141.97$141.97
20231,0691,069$144.54$144.54

States with the most M0220 services (2023)

StateServicesAvg. paid
Florida171$145.22
California135$153.23
Pennsylvania74$143.82
Texas68$141.63
Maryland56$152.22

What changed for M0220

Frequently asked questions

What is HCPCS code M0220?

M0220 is the HCPCS Level II code for injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring. Short descriptor: "Tixagev and cilgav inj".

How much does Medicare pay for M0220?

In 2023, the average Medicare payment was $144.54 per service (average allowed $144.54).

Does Medicare cover M0220?

Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.

Related M02 codes

Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.

Next steps

Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.

All M codes · HCPCS lookup